Dr. S. Vincent Rajkumar on a New Bortezomib Triplet in Multiple Myeloma
S. Vincent Rajkumar, MD, discusses bortezomib, lenalidomide, and dexamethasone coming out on top in a recent phase III trial over lenalidomide and dexamethasone alone.
S. Vincent Rajkumar, MD, professor of medicine, Mayo Clinic, discusses bortezomib, lenalidomide, and dexamethasone coming out on top in a recent phase III trial over lenalidomide and dexamethasone alone.
The findings of the phase III trial, labeled SWOG S0777, showed a 13-month improvement in progression-free survival and a 29% reduction of risk of death with the triplet of bortezomib, lenalidomide, and dexamethasone, compared with lenalidomide and dexamethasone alone. Findings from the study suggest the triplet should be a new standard of care for untreated patients with multiple myeloma. Rajkumar said the triplet is now the new standard of care at the Mayo Clinic for multiple myeloma.
Savona Discusses First-Line JAK Inhibition for Patients With Myelofibrosis at Risk of Anemia
April 17th 2024During a Case-Based Roundtable® event, Michael Savona, MD, and participants discussed the case of a patient with myelofibrosis and moderate anemia receiving JAK inhibitor therapy.
Read More
Biomarker Testing Paves the Way for Better Targeted Therapies in NSCLC
April 16th 2024At a live virtual event, Edward S. Kim, MD, MBA, discussed the evolving landscape of biomarker testing before making treatment decisions for patients with early-stage non–small cell lung cancer (NSCLC).
Read More
Creating Solutions for a 'Continual State of Transition' in Cancer Care
April 15th 2024In a Peers & Perspectives in Oncology feature article, we focus on the importance of the transition-of-care process for patients with cancer as they move from the inpatient to outpatient setting, as well as between lines of therapy with comments from Marc J. Braunstein, MD, PhD, and Michael Shusterman, MD.
Read More
